TX-FLUENCE
14.7.2022 15:02:08 CEST | Business Wire | Press release
Fluence , a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced today its exclusive partnership with BioLumic , a plant-growth biotechnology company that harnesses the power of ultraviolet (UV) light to sustainably increase plant yields, health and quality with Light Signal Recipes™. Under the agreement, Fluence and BioLumic will collaborate to deliver BioLumic’s cutting-edge UV Light Signals through Fluence’s industry-leading LED lighting solutions.
BioLumic’s patented technology leverages UV photomorphogenesis to trigger biological events in seeds and young plants to dramatically optimize plant performance. The company’s proven UV Light Signal Recipes™ can induce large gains in plant yields, desirable plant traits and vigor while also activating natural plant resistance to disease and pests.
“Our goal at Fluence is to drive cutting-edge plant science and innovations in agriculture technology,” said David Cohen, CEO of Fluence. “We’re excited to pursue that goal in collaboration with BioLumic and create the next generation of leading lighting solutions for cannabis and produce growers around the world.”
Fluence’s lighting systems will deliver BioLumic’s dynamic UV light treatments in the propagation phase of plant production—one-time treatments that trigger benefits that accrue through the entire plant growth cycle. Pairing BioLumic and Fluence’s leading market solutions enables cultivators to achieve high-quality yield gains, enhance cannabinoid levels and improve overall plant quality while reducing cycle-to-cycle variability.
“BioLumic’s Light Signal Recipes™ allow cultivators to fully and frictionlessly harness UV lighting to improve plant growth and genetic expression without big input costs or chemicals,” said Steve Sibulkin, CEO of BioLumic. “This partnership will accelerate the development of BioLumic’s Light Signal Platform, increase our company’s access to the global horticulture market and strengthen Fluence’s horticultural lighting portfolio. It’s a tremendous win for growers looking for new ways to grow more with less.”
The partnership reinforces Fluence’s deep history of science-led innovation in photobiology and follows several product launches this year, including RAPTR, RAZR Modular System, VYNE, SPYDR Fang, SPYDR 2h and Wireless Flex Dimming. Fluence’s dynamic and expanding suite of luminaires and lighting controls empowers growers with advanced lighting technology that meets and exceeds cultivation goals.
Fluence and BioLumic will initially work with select cannabis cultivation partners while industrializing commercial delivery systems for UV light that enhance Fluence’s end-to-end product offering in 2023. For more information about BioLumic, please visit www.biolumic.com . For more information about Fluence, visit www.fluence.science .
About Fluence
Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence.science .
About BioLumic
BioLumic is an agricultural biotech company that programs plants with light to unlock growth, quality and disease-resistance. The company's Light Signal Recipe™ platform combines biological insights and genetic marker knowledge to mediate genetic expression with a one-time application of light signals. These treatments are scalable and require no chemical application, genetic modification, facility expansion or large input costs. BioLumic has worked with 12 crops, including cannabis, soybeans, corn, leafy greens and strawberries. In cannabis, the company has helped cultivators produce large double-digit gains in dry flower yield, THC concentration, minor cannabinoids and terpene expression. To learn more, visit www.biolumic.com or send an email to info@biolumic.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220714005019/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom